Press coverage about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cardiome Pharma earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 44.7756165076503 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Cardiome Pharma (NASDAQ CRME) traded up $0.02 during trading on Thursday, hitting $1.59. The company had a trading volume of 45,400 shares, compared to its average volume of 62,000. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. The company has a market cap of $54.92, a P/E ratio of -1.92 and a beta of 0.83. Cardiome Pharma has a 1-year low of $1.29 and a 1-year high of $4.84.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.04). The company had revenue of $6.02 million for the quarter, compared to the consensus estimate of $7.42 million. Cardiome Pharma had a negative return on equity of 94.68% and a negative net margin of 112.91%. Cardiome Pharma’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.19) EPS. sell-side analysts anticipate that Cardiome Pharma will post -0.84 EPS for the current year.

A number of analysts have commented on CRME shares. Zacks Investment Research upgraded Cardiome Pharma from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Wednesday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $9.50 price objective on shares of Cardiome Pharma in a research report on Wednesday, November 22nd. Canaccord Genuity set a $5.00 price objective on Cardiome Pharma and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Finally, Mackie upgraded Cardiome Pharma to a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.50.

TRADEMARK VIOLATION WARNING: “Cardiome Pharma (CRME) Given Media Sentiment Score of 0.19” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2018/01/04/cardiome-pharma-crme-given-media-sentiment-score-of-0-19.html.

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Insider Buying and Selling by Quarter for Cardiome Pharma (NASDAQ:CRME)

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.